C G Plopper, J P Joad, L A Miller, E S Schelegle, M V Fanucchi, L S Van Winkle, N K Tyler, M V Avdalovic, M J Evans, W L Lasley, A R Buckpitt, K E Pinkerton, B K Tarkington, S Davis, S J Nishio, L J Gershwin, R Wu, D M Hyde
BACKGROUND: The risks for infants and young children receiving inhaled corticosteroid (ICS) therapy are largely unknown. Recent clinical studies indicate that ICS therapy in pre-school children with symptoms of asthma result in decreased symptoms without influencing the clinical disease course, but potentially affect postnatal growth and development. The current study employs a primate experimental model to identify the risks posed by ICS therapy. OBJECTIVE: To (1) establish whether ICS therapy in developing primate lungs reverses pulmonary pathobiology associated with allergic airway disease (AAD) and (2) define the impact of ICS on postnatal lung growth and development in primates...
July 2012: Clinical and Experimental Allergy